TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advantages and Disadvantages of Long Term Sedation in ICU Patients
Brief Summary: The purpose of the study is to determine whether sedation of the critical ill patient prolongs the time receiving mechanical ventilation.


Options:
A: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A
B: Arm Label: 1. Intermittent sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intermittent sedation | Arm Label: 2. Daily interruption of sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Daily interruption of sedation | Intervention Type: PROCEDURE; Name: Intermittent sedation; Assigned to Arm(s): 1. Intermittent sedation | Intervention Type: PROCEDURE; Name: Daily interruption of sedation; Assigned to Arm(s): 2. Daily interruption of sedation
C: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
D: Intervention Type: PROCEDURE; Name: Daily interruption of sedation versus sedation algorithm; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advantages and Disadvantages of Long Term Sedation in ICU Patients
Brief Summary: The purpose of the study is to determine whether sedation of the critical ill patient prolongs the time receiving mechanical ventilation.


Options:
A: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine
B: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
D: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Dilapan-S, vitamin B-12 | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Dilapan-S, vitamin B-12; Assigned to Arm(s): 2
D: Arm Label: hospital- based vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: vaginal misoprostol | Arm Label: extended low dose oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: buccal/sublingual misoprostol | Intervention Type: DRUG; Name: vaginal misoprostol; Assigned to Arm(s): hospital- based vaginal misoprostol | Intervention Type: DRUG; Name: buccal/sublingual misoprostol; Assigned to Arm(s): extended low dose oral misoprostol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
B: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group
C: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
C: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.


Options:
A: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
C: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with advanced clear cell carcinoma of the kidney.


Options:
A: Arm Label: Ipilimumab plus nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab plus nivolumab | Arm Label: Standard of Care therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Therapy | Intervention Type: DRUG; Name: Ipilimumab plus nivolumab; Assigned to Arm(s): Ipilimumab plus nivolumab | Intervention Type: DRUG; Name: Standard Therapy; Assigned to Arm(s): Standard of Care therapy
B: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: Doublet; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cabozantinib | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Triplet; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Triplet
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with advanced clear cell carcinoma of the kidney.


Options:
A: Intervention Type: DRUG; Name: autologous human tumor-derived HSPPC-96; Assigned to Arm(s): N/A
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
C: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with advanced clear cell carcinoma of the kidney.


Options:
A: Arm Label: A; Type: OTHER; Interventions: Drug: axitinib | Arm Label: B; Type: OTHER; Interventions: Drug: axitinib | Arm Label: C; Type: OTHER; Interventions: Drug: axitinib | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): C
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
D: Arm Label: RAD001 +BSC; Type: EXPERIMENTAL; Interventions: Drug: RAD001 | Arm Label: Placebo (plus BSC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): RAD001 +BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (plus BSC)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Daily Calorie Restriction or Alternate-day Reductions in Calorie Intake on Risk for Cardiovascular Disease and Cancer
Brief Summary: The purpose of this study is to examine and compare the effects of alternate-day reductions in calorie intake or daily calorie restriction on the risk for cardiovascular disease and cancer.


Options:
A: Arm Label: Fasting Day First; Type: OTHER; Interventions: Behavioral: Fasting First | Arm Label: Fed Day First; Type: OTHER; Interventions: Behavioral: Fed First | Intervention Type: BEHAVIORAL; Name: Fasting First; Assigned to Arm(s): Fasting Day First | Intervention Type: BEHAVIORAL; Name: Fed First; Assigned to Arm(s): Fed Day First
B: Arm Label: Low energy dense; Type: EXPERIMENTAL; Interventions: Other: low energy dense, Other: diet | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control, Other: diet | Intervention Type: OTHER; Name: low energy dense; Assigned to Arm(s): Low energy dense | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control | Intervention Type: OTHER; Name: diet; Assigned to Arm(s): Low energy dense, control
C: Arm Label: intermittent energy restriction; Type: EXPERIMENTAL; Interventions: Other: dietary intervention intermittent energy restriction | Arm Label: continuous energy restriction; Type: ACTIVE_COMPARATOR; Interventions: Other: continuous energy restriction | Intervention Type: OTHER; Name: dietary intervention intermittent energy restriction; Assigned to Arm(s): intermittent energy restriction | Intervention Type: OTHER; Name: continuous energy restriction; Assigned to Arm(s): continuous energy restriction
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Alternate Day Fasting Arm; Type: OTHER; Interventions: Behavioral: calorie restriction | Arm Label: Calorie Restriction; Type: OTHER; Interventions: Behavioral: calorie restriction | Intervention Type: BEHAVIORAL; Name: calorie restriction; Assigned to Arm(s): Alternate Day Fasting Arm, Calorie Restriction

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
Brief Summary: The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.


Options:
A: Arm Label: aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: blank; Type: OTHER; Interventions: Other: Blank | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin | Intervention Type: OTHER; Name: Blank; Assigned to Arm(s): blank
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
C: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Control Arm
D: Arm Label: Intervention Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: B